agree other issues w the report as well - citing competitive concerns for example when after MRK there isn't anyone close (assuming BMy bows out), GILD pan genotypic drug won't effect the GT1 landscape (and may be perceive as inferior to harvoni - as evidenced by the 8 week data), the fact ABBV next gen is pan genotypic which can open up the non-GT1 market to them, and most of all there just isn't much room for improvement any more - is going from 8 to 6 weeks going to mean much?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.